
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a petition before the Kerala High Court seeking government intervention to make two expensive breast cancer drugs more affordable,




